The first three EU Joint Clinical Assessments are now public and provide an early view of how the new EU HTA framework assesses comparative evidence.
We went through all the three JCAs in depth to draw key insights. Our latest ANSEA Insights report analyses the assessments for tovorafenib, tarlatamab, and lurbinectedin, examining what they reveal about comparative evidence, evidence gaps, and the future of EU HTA.
Key take away is that the JCA process does not remove uncertainty where the evidence remains limited. Instead, it makes evidence gaps and their relevance across European markets more visible.
For manufacturers, HEOR teams, and market access teams, this means planning beyond pivotal trials to ensure evidence packages are fit for both EU assessment and national reimbursement decisions.
